Rational evolution of a novel type of potent and selective proviral integration site in moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 5151-5164

  Nakano, Hirofumi ^a   Saito, Nae ^a   Parker, Lorien ^b   Tada, Yukio ^a   Abe, Masanao ^a   Tsuganezawa, Keiko ^b   Yokoyama, Shigeyuki ^a,b   Tanaka, Akiko ^a,b   Kojima, Hirotatsu ^a   Okabe, Takayoshi ^a   Nagano, Tetsuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(1H INDAZOL 3 YL)METHYLENE] 6 METHOXY 7 (PIPERAZIN 1 YLMETHYL)BENZOFURAN 3(2H) ONE; 2 [(1H INDOL 3 YL)METHYLENE] 6 HYDROXY 7 (PIPERAZIN 1 YLMETHYL)BENZOFURAN 3(2H)ONE; 2 [(1H INDOL 3 YL)METHYLENE] 6 HYDROXY 7 [(4 METHYLPIPERAZIN 1 YL)METHYL]BENZOFURAN 3(2H)ONE; 2 [(1H INDOL 3 YL)METHYLENE] 6 METHOXY 7 (PIPERAZIN 1 YLMETHYL)BENZOFURAN 3(2H)ONE; 2 [(1H INDOL 3 YL)METHYLENE] 7 (AZEPAN 1 YLMETHYL) 6 HYDROXYBENZOFURAN 3(2)ONE; 2 [(1H INDOL 3 YL)METHYLENE] 7 (PIPERAZIN 1 YLMETHYL)BENZOFURAN 3(2H)ONE; 2 [(1H PYRROLO[2,3-B]PYRIDIN 3 YL)METHYLENE] 6 METHOXY 7 (PIPERAZIN 1 YLMETHYL)BENZOFURAN 3(2H)ONE; 2 [(1H PYRROLO[2,3-C]PYRIDIN 3 YL)METHYLENE] 6 METHOXY 7 (PIPERAZIN 1 YLMETHYL)BENZOFURAN 3(2H)ONE; 2 [(1H PYRROLO[3,2-B]PYRIDIN 3 YL)METHYLENE] 6 METHOXY 7 (PIPERAZIN 1 YLMETHYL)BENZOFURAN 3(2H)ONE; 2 [(1H PYRROLO[3,2-C]PYRIDIN 3 YL)METHYLENE] 6 METHOXY 7 (PIPERAZIN 1 YLMETHYL)BENZOFURAN 3(2H)ONE; 7 [(1,4 DIAZEPAN 1 YL)METHYL] 2 [(1H INDOL 3 YL)METHYLENE] 6 HYDROXYBENZOFURAN 3(2H)ONE; ANTINEOPLASTIC AGENT; MOLONEY MURINE LEUKEMIA VIRUS KINASE 1 INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIPOPHILICITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZA COMPOUNDS; BENZOFURANS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; HUMANS; INDOLES; LEUKEMIA; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTO-ONCOGENE PROTEINS C-PIM-1; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862285781     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3001289     Document Type: Article

References (74)

1. Brault, L.; Gasser, C.; Bracher, F.; Huber, K.; Knapp, S.; Schwaller, J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers Haematologica 2010, 95, 1004-1015
2. Magnuson, N. S.; Wang, Z.; Ding, G.; Reeves, R. Why target PIM1 for cancer diagnosis and treatment? Future Oncol. 2010, 6, 1461-1478
3. Amson, R.; Sigaux, F.; Przedborski, S.; Flandrin, G.; Givol, D.; Telerman, A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8857-8861
4. Dhanasekaran, S. M.; Barrette, T. R.; Ghosh, D.; Shah, R.; Varambally, S.; Kurachi, K.; Pienta, K. J.; Rubin, M. A.; Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer Nature 2001, 412, 822-826
5. r 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells Cancer Res. 1997, 57, 5348-5355
6. van Lohuizen, M.; Verbeek, S.; Krimpenfort, P.; Domen, J.; Saris, C.; Radaszkiewicz, T.; Berns, A. Predisposition to lymphomagenesis in pim -1 transgenic mice: cooperation with c- myc and N- myc in murine leukemia virus-induced tumors Cell 1989, 56, 673-682
7. Breuer, M.; Slebos, R.; Verbeek, S.; van Lohuizen, M.; Wientjens, E.; Berns, A. Very high frequency of lymphoma induction by a chemical carcinogen in pim -1 transgenic mice Nature 1989, 340, 61-63
8. 112 gatekeeper site FEBS Lett. 2004, 571, 43-49
9. Zhang, Y.; Wang, Z.; Li, X.; Magnuson, N. S. Pim kinase-dependent inhibition of c-Myc degradation Oncogene 2008, 27, 4809-4819
10. Zippo, A.; De Robertis, A.; Serafini, R.; Oliviero, S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation Nature Cell Biol. 2007, 9, 932-944
11. Cip1/WAF1 regulates its stability and cellular localization in H1299 cells Mol. Cancer Res. 2007, 5, 909-922
12. Kip1 at the transcriptional and posttranscriptional levels Cancer Res. 2008, 68, 5076-5085
13. Mochizuki, T.; Kitanaka, C.; Noguchi, K.; Muramatsu, T.; Asai, A.; Kuchino, Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase J. Biol. Chem. 1999, 274, 18659-18666
14. Bachmann, M.; Kosan, C.; Xing, P. X.; Montenarh, M.; Hoffmann, I.; Möröy, T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C Int. J. Biochem. Cell Biol. 2006, 38, 430-443
15. Grundler, R.; Brault, L.; Gasser, C.; Bullock, A. N.; Dechow, T.; Woetzel, S.; Pogacic, V.; Villa, A.; Ehret, S.; Berridge, G.; Spoo, A.; Dierks, C.; Biondi, A.; Knapp, S.; Duyster, J.; Schwaller, J. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration J. Exp. Med. 2009, 206, 1957-1970
16. Xie, Y.; Burcu, M.; Linn, D. E.; Qiu, Y.; Baer, M. R. Pim-1 kinase protects p-glycoprotein from degradation and enables its glycosylation and cell surface expression Mol. Pharmacol. 2010, 78, 310-318
17. Xie, Y.; Xu, K.; Linn, D. E.; Yang, X.; Guo, Z.; Shimelis, H.; Nakanishi, T.; Ross, D. D.; Chen, H.; Fazli, L.; Gleave, M. E.; Qiu, Y. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells J. Biol. Chem. 2008, 283, 3349-3356
18. Laird, P. W.; van der Lugt, N. M. T.; Clarke, A.; Domen, J.; Linders, K.; McWhir, J.; Berns, A.; Hooper, M. In vivo analysis of Pim -1 deficiency Nucleic Acids Res. 1993, 21, 4750-4755
19. Morwick, T. Pim kinase inhibitors: a survey of the patent literature Expert Opin. Ther. Pat. 2010, 20, 193-212
20. Bullock, A. N.; Debreczeni, J. é.; Fedorov, O. Y.; Nelson, A.; Marsden, B. D.; Knapp, S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase J. Med. Chem. 2005, 48, 7604-7614
21. Pogacic, V.; Bullock, A. N.; Fedorov, O.; Filippakopoulos, P.; Gasser, C.; Biondi, A.; Meyer-Monard, S.; Knapp, S.; Schwaller, J. Structural analysis identifies imidazo[1,2- b ]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity Cancer Res. 2007, 67, 6916-6924
22. Chen, L. S.; Redkar, S.; Bearss, D.; Wierda, W. G.; Gandhi, V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells Blood 2009, 114, 4150-4157
23. Mumenthaler, S. M.; Ng, P. Y. B.; Hodge, A.; Bearss, D.; Berk, G.; Kanekal, S.; Redkar, S.; Taverna, P.; Agus, D. B.; Jain, A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes Mol. Cancer Ther. 2009, 8, 2882-2893
24. Chen, L. S.; Redkar, S.; Taverna, P.; Cortes, J. E.; Gandhi, V. Mechanism of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia Blood 2011, 118, 693-702
25. Debreczeni, J. é.; Bullock, A. N.; Atilla, G. E.; Williams, D. S.; Bregman, H.; Knapp, S.; Meggers, E. Ruthenium half-sandwitch complexes bound to protein kinase Pim-1 Angew. Chem., Int. Ed. Engl. 2006, 45, 1580-1585
26. Cheney, I. W.; Yan, S.; Appleby, T.; Walker, H.; Vo, T.; Yao, N.; Hamatake, R.; Hong, Z.; Wu, J. Z. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase Bioorg. Med. Chem. Lett. 2007, 17, 1679-1683
27. Tong, Y.; Stewart, K. D.; Thomas, S.; Przytulinska, M.; Johnson, E. F.; Klinghofer, V.; Leverson, J.; McCall, O.; Soni, N. B.; Luo, Y.; Lin, N.-H.; Sowin, T. J.; Giranda, V. L.; Penning, T. D. Isoxazolo[3,4- b ]quinoline-3,4(1 H,9 H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling Bioorg. Med. Chem. Lett. 2008, 18, 5206-5208
28. Xia, Z.; Knaak, C.; Ma, J.; Beharry, Z. M.; McInnes, C.; Wang, W.; Kraft, A. S.; Smith, C. D. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases J. Med. Chem. 2009, 52, 74-86
29. Beharry, Z.; Zemskova, M.; Mahajan, S.; Zhang, F.; Ma, J.; Xia, Z.; Lilly, M.; Smith, C. D.; Kraft, A. S. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells Mol. Cancer Ther. 2009, 8, 1473-1483
30. Grey, R.; Pierce, A. C.; Bemis, G. W.; Jacobs, M. D.; Moody, C. S.; Jajoo, R.; Mohal, N.; Green, J. Structure-based design of 3-aryl-6-amino- triazolo[4,3- b ]pyridazine inhibitors of Pim-1 kinase Bioorg. Med. Chem. Lett. 2009, 19, 3019-3022
31. Qian, K.; Wang, L.; Cywin, C. L.; Farmer, B. T., II; Hickey, E.; Homon, C.; Jakes, S.; Kashem, M. A.; Lee, G.; Leonard, S.; Li, J.; Magboo, R.; Mao, W.; Pack, E.; Peng, C.; Prokopowicz, A., III; Welzel, M.; Wolak, J.; Morwick, T. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode J. Med. Chem. 2009, 52, 1814-1827
32. Akué-Gédu, R.; Rossignol, E.; Azzaro, S.; Knapp, S.; Filippakopoulos, P.; Bullock, A. N.; Bain, J.; Cohen, P.; Prudhomme, M.; Anizon, F.; Moreau, P. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors J. Med. Chem. 2009, 52, 6369-6381
33. Tao, Z.-F.; Hasvold, L. A.; Leverson, J. D.; Han, E. K.; Guan, R.; Johnson, E. F.; Stoll, V. S.; Stewart, K. D.; Stamper, G.; Soni, N.; Bouska, J. J.; Luo, Y.; Sowin, T. J.; Lin, N.-H.; Giranda, V. S.; Rosenberg, S. H.; Penning, T. D. Discovery of 3 H -benzo[4,5]thieno[3,2- d ]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases J. Med. Chem. 2009, 52, 6621-6636
34. Ren, J.-X.; Li, L.-L.; Zheng, R.-L.; Xie, H.-Z.; Cao, Z.-X.; Feng, S.; Pan, Y.-L.; Chen, X.; Wei, Y.-Q.; Yang, S.-Y. Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking J. Chem. Inf. Model. 2011, 51, 1364-1375
35. Xiang, Y.; Hirth, B.; Asmussen, G.; Biemann, H.-P.; Bishop, K. A.; Good, A.; Fitzgerald, M.; Gladysheva, T.; Jain, A.; Jancsics, K.; Liu, J.; Metz, M.; Papoulis, A.; Skerlj, R.; Stepp, J. D.; Wei, R. R. The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 3050-3056
36. Nishiguchi, G. A.; Atallah, G.; Bellamacina, C.; Burger, M. T.; Ding, Y.; Feucht, P. H.; Garcia, P. D.; Han, W.; Klivansky, L.; Lindvall, M. Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 kinases Bioorg. Med. Chem. Lett. 2011, 21, 6366-6369
37. Pierre, F.; Stefan, E.; Nédellec, A.-S.; Chevrel, M.-C.; Regan, C. F.; Siddiqui-Jain, A.; Macalino, D.; Streiner, N.; Drygin, D.; Haddach, M.; O'Brien, S. E.; Anderes, K.; Ryckman, D. M. 7-(4 H -1,2,4-Triazol-3-yl)benzo[ c ][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity Bioorg. Med. Chem. Lett. 2011, 21, 6687-6692
38. Huber, K.; Brault, L.; Fedorov, O.; Gasser, C.; Filippakopoulos, P.; Bullock, A. N.; Fabbro, D.; Trappe, J.; Schwaller, J.; Knapp, S.; Bracher, F. 7,8-Dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes J. Med. Chem. 2012, 55, 403-413
39. Haddach, M.; Michaux, J.; Schwaebe, M. K.; Pierre, F.; O'Brien, S. E.; Borsan, C.; Tran, J.; Raffaele, N.; Ravula, S.; Drygin, D.; Siddiqui-Jain, A.; Darjania, L.; Stansfield, R.; Proffitt, C.; Macalino, D.; Streiner, N.; Bliesath, J.; Omori, M.; Whitten, J. P.; Anderes, K.; Rice, W. G.; Ryckman, D. M. Discovery of CX-6258. A potent, selective, and orally efficacious pan-Pim kinases inhibitor ACS Med. Chem. Lett. 2012, 3, 135-139
40. Blanco-Aparicio, C.; Collazo, A. M. G.; Oyarzabal, J.; Leal, J. F.; Albarán, M. I.; Lima, F. R.; Pequeño, B.; Ajenjo, N.; Becerra, M.; Alfonso, P.; Reymundo, M. I.; Palacios, I.; Mateos, G.; Quiñones, H.; Corrionero, A.; Carnero, A.; Pevarello, P.; Lopez, A. R.; Forminaya, J.; Pastor, J.; Bischoff, J. R. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition Cancer Lett. 2011, 300, 145-153
41. Sliman, F.; Blairvacq, M.; Durieu, E.; Meijer, L.; Rodrigo, J.; Desmaële, D. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase Bioorg. Med. Chem. Lett. 2010, 20, 2801-2805
42. Olla, S.; Manetti, F.; Crespan, E.; Maga, G.; Angelucci, A.; Schenone, S.; Bologna, M.; Botta, M. Indolyl-pyrrolone as new scaffold for Pim1 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 1512-1516
43. Tsuganezawa, K.; Watanabe, H.; Parker, L.; Yuki, H.; Taruya, S.; Nakagawa, Y.; Kamei, D.; Mori, M.; Ogawa, N.; Tomabechi, Y.; Handa, N.; Honma, T.; Yokoyama, S.; Kojima, H.; Okabe, T.; Nagano, T.; Tanaka, A. A novel Pim-1 kinase inhibitor targeting residues that bind the substrate peptide J. Mol. Biol. 2012, 417, 240-252
44. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C. J.; McLauchlan, H.; Klevernic, I.; Arthur, J. S. C.; Alessi, D. R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update Biochem. J. 2007, 408, 297-315
45. Nassar, A.-E. F.; Kamel, A. M.; Clarimont, C. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability Drug Discovery Today 2004, 9, 1020-1028
46. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834
47. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315
48. Friedmann, M.; Nissen, M. S.; Hoover, D. S.; Reeves, R.; Magnuson, N. S. Characterization of the proto-oncogene Pim-1: kinase activity and substrate recognition sequence Arch. Biochem. Biophys. 1992, 298, 594-601
49. Qian, K. C.; Wang, L.; Hickey, E. R.; Studts, J.; Barringer, K.; Peng, C.; Kronkaitis, A.; Li, J.; White, A.; Mische, S.; Farmer, B. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase J. Biol. Chem. 2005, 280, 6130-6137
50. Pierce, A. C.; Jacobs, M.; Stuver-Moody, C. Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase J. Med. Chem. 2008, 51, 1972-1975
51. Cherry, M.; Williams, D. H. Recent kinase and kinase inhibitor X-ray structures: mechanism of inhibition and selectivity insights Curr. Med. Chem. 2004, 11, 663-673
52. Thaimattam, R.; Banerjee, R.; Miglani, R.; Iqbal, J. Protein kinase inhibitors: structural insights into selectivity Curr. Pharm. Des. 2007, 13, 2751-2765
53. Swahn, B.-M.; Huerta, F.; Kallin, E.; Malmström, J.; Weigelt, T.; Viklund, J.; Womack, P.; Xue, Y.; Öhberg, L. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3 Bioorg. Med. Chem. Lett. 2005, 15, 5095-5099
54. Perola, E. Minimizing false positives in kinase virtual screens Proteins 2006, 64, 422-435
55. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
56. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Rev. Drug Discovery 2007, 6, 881-890
57. 50) - cLogP; Edwards, M. P.; Price, D. A. Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks Annu. Rep. Med. Chem. 2010, 45, 381-391
58. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S. M.; Fong, D.; Zhu, Y.-L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S.-H.; Schlessinger, J.; Zhang, K. Y. J.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3041-3046
59. Kim, K.-T.; Levis, M.; Small, D. Constitutively activated FLT3 phosphorylates BAD partially through Pim-1 Br. J. Hamaetol. 2006, 134, 500-509
60. Kerns, E. H.; Di, L. Drug-Like Properties: Concepts, Structure Design, and Methods; Academic Press: New York, 2008.
61. Liu, X.; Gourley, E.; Lamb, J.; Grand, C.; Lloyd, M.; Warner, S.; Wolfe, B.; Bearss, D.; Vankayalapati, H. Discovery of SGI-1776, a potent and selective Pim-1 kinase inhibitor. AACR 2009 Annual Meeting, Denver, Colorado, April 18-22, 2009, Abstract No. 2013.
62. 50 value of 1 μM. (http://astx.com/content/resources/2011-PIM-poster-EORTC-abstC200-Foulks.pdf): Foulks, J. M.; Xu, Y.; Saunders, M.; Liu, X.-H.; Brenning, B.; Clifford, A.; Wilkes, M.; Luo, B.; Lai, S.; Merx, S.; Chan, A.; Huang, L.; Vollmer, D.; Senina, A.; Liu, J.; Ho, K.; McCullar, M. V.; Kanner, S. B. Second-generation PIM inhibitors exhibit improved activity in solid tumor models in vitro. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, Nov 12-16, 2011. Mol. Cancer Ther. 2011, 10 (11, Suppl 1), Abstract no. C200.
63. Chen, J.; Shi, Z.-F.; Zhou, L.; Xie, A.-L.; Cao, X.-P. Total synthesis of malyngamide M and isomalyngamide M Tetrahedron 2010, 66, 3499-3507
64. For the synthesis of 4-azaindole-3-aldehyde: Greenhouse, R.; Jamie-Figueroa, S.; Lynch, S. M.; Raptova, L.; Stein, K. A.; Weikert, R. J. 3-Amino-1-arylpropyl azaindoles and uses thereof. US 2007/0123535, 2007.
65. For the synthesis of 5-azaindole-3-aldehyde: Bradbury, R. H.; Hales, N. J.; Rabow, A. A. Bicyclic derivatives for use in the treatment of androgen receptor associated conditions. WO 2009/081197, 2009.
66. Kigawa, T.; Yabuki, T.; Matsuda, N.; Matsuda, T.; Nakajima, R.; Tanaka, A.; Yokoyama, S. Preparation of Escherichia coli cell extract for highly productive cell-free protein expression J. Struct. Funct. Genomics 2004, 5, 63-68
67. Matsuda, T.; Koshiba, S.; Tochio, N.; Seki, E.; Iwasaki, N.; Yabuki, T.; Inoue, M.; Yokoyama, S.; Kigawa, T. Improving cell-free protein synthesis for stable-isotope labeling J. Biomol. NMR 2007, 37, 225-229
68. Kigawa, T.; Matsuda, T.; Yabuki, T.; Yokoyama, S. Bacterial cell-free system for highly efficient protein synthesis. In Cell-Free Protein Synthesis: Methods and Protocols; Spirin, A. S.; Swartz, J. R., Eds.; Wiley-VCH: Weinheim, Germany, 2007; pp 83-97.
69. Jacobs, M. D.; Black, J.; Futer, O.; Swenson, L.; Hare, B.; Fleming, M.; Saxena, K. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002 J. Biol. Chem. 2005, 280, 13728-13734
70. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography 1992, 26.
71. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta. Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
72. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674
73. Murshudov, G. N.; Vagin, A. A; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
74. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132